Entity

Time filter

Source Type

Calgary, Canada

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that focuses on the development of pharmaceutical products for the treatment of human cancers. The product Reolysin harnesses the oncolytic capabilities of naturally-occurring reovirus , which has been shown to replicate specifically in cells with an activated Ras pathway. Ras pathway mutations are found in approximately two thirds of all tumours, including most metastatic disease, which makes Reolysin a potential therapeutic for cancer. Wikipedia.


Patent
Oncolytics Biotech | Date: 2015-04-23

Provided herein are liquid viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The liquid viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients and a liquid carrier. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.


Patent
Oncolytics Biotech | Date: 2015-04-22

Provided herein are lyophilized viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The lyophilized viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.


Patent
Oncolytics Biotech | Date: 2012-04-27

Provided herein are elution buffers and methods for purifying viruses using gel permeation chromatography. The methods are useful, for example, in increasing recovery of a virus from a gel permeation chromatography column. The buffers for use in the methods include at least one excipient selected from histidine or sucrose, a divalent cation, a non-ionic detergent, and a phosphate buffered saline.


Patent
Oncolytics Biotech | Date: 2014-02-13

The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.


Patent
Oncolytics Biotech | Date: 2012-09-27

The present invention provides a method of detecting adventitious agents in a composition comprising a microorganism by using ribozyme-expressing indicator cells, as well as indicator cells useful in such detection.

Discover hidden collaborations